Qualigen Therapeutics Inc

-0.06 (-2.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)60.26M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.7 Million
Adjusted EPS-$0.18
See more estimates
10-Day MA$2.08
50-Day MA$2.00
200-Day MA$3.34
See more pivots

Qualigen Therapeutics Inc Stock, NASDAQ:QLGN

1880 Century Park East, Suite 3000, Los Angeles, California 90067
United States of America
Phone: +1.310.203.1000
Number of Employees:


Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.